Navigation Links
DURECT Corporation Announces Fourth Quarter and Year End 2010 Financial Results
Date:3/2/2011

y developing innovative drugs for pain and chronic diseases, with late-stage development programs including REMOXY®, POSIDUR™, ELADUR®, and TRANSDUR®-Sufentanil.  DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.  For more information, please visit www.durect.com.

NOTE: POSIDUR™, SABER™, ORADUR®, TRANSDUR®, ELADUR®, and DURIN® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

DURECT Forward-Looking StatementThe statements in this press release regarding the potential approval and timing of approval of REMOXY by the FDA and subsequent product launch by Pfizer, our anticipated net cash consumption, anticipated clinical trials (including timing and results) for POSIDUR, TRANSDUR-Sufentanil, ELADUR, ORADUR-ADHD and our other drug candidates, the potential benefits and uses of our drug candidates and potential collaborations with third parties are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risk of adverse decisions by regulatory agencies, including product non-approval, delays and additional costs due to requirements imposed by regulatory agencies, potential adverse effects arising from the testing or use of our drug candidates, the potential failure of our clinical trials to meet their intended e
'/>"/>

SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. DURECTs Collaboration With Alpharma Clears HSR Review and Is Effective
2. DURECT Corporation Announces Third Quarter 2008 Financial Results
3. DURECT Corporation Invites You to Join its Third Quarter 2010 Earnings Conference Call
4. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
5. Pharmos Corporation Reports 2008 Second Quarter Results
6. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
7. Genaera Corporation Announces Second Quarter Financial Results
8. MannKind Corporation Reports Second Quarter Financial Results
9. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
10. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
11. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... cell fragments whose job it is to stop bleeding, ... But they can "feel" the physical environment around them, ... Platelets respond to surfaces with greater stiffness by increasing ... other platelets and other components of the clotting system, ... give them credit for, in that they are able ...
(Date:9/22/2014)... a highly sensitive chemical sensor based on the crystalline ... properties that the researchers were able to exploit to ... , The study is available online in advance of ... Khojin, asst professor of mechanical and industrial engineering in ... Kumar, post doc where they are doing research in ...
(Date:9/22/2014)... NY (PRWEB) September 22, 2014 Topical ... helping those in pain end their suffering, restoring hope ... healthcare model. This is only possible because of the ... and healing cream technology a reality. , The ... Rhinebeck, NY, by Lou Paradise (president, chief of research, ...
(Date:9/22/2014)... 22, 2014 Invisible Sentinel Inc., ... the food and beverage industries, announced today that ... under a non-exclusive agreement by Enartis, a global ... Enartis, an Esseco Group company headquartered in Trecate, ... California and other global markets for their own ...
Breaking Biology Technology:Platelets modulate clotting behavior by 'feeling' their surroundings 2Graphene imperfections key to creating hypersensitive 'electronic nose' 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 4Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 5Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 6Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 2Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 3
... ... and Genedata Expressionist® at Evonik for Industrial Biotechnology R&D Processes , ... Basel, Switzerland (PRWEB) ... industrial biotechnology R&D, today announced an extended partnership with Evonik, a leading life ...
... ... ... , ... , , , ...
... in the development of practical phonon lasers, which emit sound ... The development should lead to new, high-resolution imaging devices and ... countless, ubiquitous devices, a phonon laser is likely to be ... Two separate research groups, one located in the US and ...
Cached Biology Technology:Evonik Extends Long-term Research & Development Partnership with Genedata 2Evonik Extends Long-term Research & Development Partnership with Genedata 3Evonik Extends Long-term Research & Development Partnership with Genedata 4Sanaria Inc. Receives Multi-Year U.S. NIH Phase II Small Business Innovation Research Grant to Develop a Genetically Attenuated Whole Parasite Malaria Vaccine 2Sanaria Inc. Receives Multi-Year U.S. NIH Phase II Small Business Innovation Research Grant to Develop a Genetically Attenuated Whole Parasite Malaria Vaccine 3Sanaria Inc. Receives Multi-Year U.S. NIH Phase II Small Business Innovation Research Grant to Develop a Genetically Attenuated Whole Parasite Malaria Vaccine 4Quantum leap for phonon lasers 2
(Date:9/21/2014)... what was previously thought, newborn immune T cells may ... bacteria, according to a new study led by King,s ... to that of adults, babies may still be able ... published in the journal Nature Medicine . , ... types of immune cells, including neutrophils which play an ...
(Date:9/19/2014)... by researchers from several Harvard University labs in ... and aspiring researchers with the intellectual raw materials ... from soft, flexible materials. , With the advent ... advances in manufacturing technology, soft robotics is emerging ... from conventional rigid robot design, but working with ...
(Date:9/19/2014)... are a species which over thousands of years has adapted ... a substance that makes the cold dangerous for you. , ... albidus , and the cold provoking substance, called nonylphenol, comes ... Nonylphenol is suspected of being a endocrine disruptor, but when ... the worm,s ability to protect the cells in its body ...
Breaking Biology News(10 mins):Immune system of newborn babies is stronger than previously thought 2Soft robotics 'toolkit' features everything a robot-maker needs 2Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3
... average life expectancy and decreases recurrences of tumors in ... according to researchers at Rhode Island Hospital. , In ... the median survival rate at three years increased from ... thermal ablation was followed by radiation for treatment of ...
... a study comparing wild rodents with their laboratory counterparts, ... that may help to explain why people in industrialized ... allergy and autoimmune diseases than do people in less ... or considered less critical. , The prevailing hypothesis concerning ...
... week's Analytical Chemistry, scientists at Indiana University Bloomington ... to follow the weakest of scents. Even when ... cells still found their mark. , A video ... a chemical gradient) can be downloaded at ...
Cached Biology News:Combined treatment extends life expectancy for lung cancer patients 2Combined treatment extends life expectancy for lung cancer patients 3Wild vs. lab rodent comparison supports hygiene hypothesis 2Wild vs. lab rodent comparison supports hygiene hypothesis 3Wild vs. lab rodent comparison supports hygiene hypothesis 4Even when faint, ovary scent draws sperm cells 2
Proliferin (C-14)...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
... Ascent is a dedicated fluorometer ... all kinds of assays in ... for clinical applications. Cell biology, ... all important application areas. Robot-friendly ...
... Thermo Savant's latest SpeedVac Concentrator, the ... and adds a new modern twist., The ... controller and gauge for optimizing runs; preventing ... to be stopped at the end-users preset ...
Biology Products: